2017
DOI: 10.1021/acs.cgd.6b01638
|View full text |Cite
|
Sign up to set email alerts
|

A Newly Discovered Racemic Compound of Pioglitazone Hydrochloride Is More Stable than the Commercial Conglomerate

Abstract: A novel racemic compound of pioglitazone hydrochloride is discovered 17 years after the FDA approval of the conglomerate. The racemic compound shows a lower dissolution rate than the conglomerate in simulated gastric fluid at room temperature and is more thermodynamically stable as evidenced by solubility measurements. Slurry transformation of a mixture of the two forms converts fully to the racemic compound. This report highlights the necessity to thoroughly explore solid forms to access the most thermodynami… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 23 publications
0
8
0
Order By: Relevance
“…13−15 The importance of understanding the interaction between enantiomers of chiral compounds used as pharmaceuticals 16,17 has been highlighted through a recent report of a more stable racemic form of pioglitazone hydrochloride, which has been marketed as a conglomerate for many years. 18 One of the common, inexpensive methods to resolve the enantiomers of a compound on an industrial scale is the entrainment procedure, where the desired enantiomer is used as a seed in the crystallization step to obtain a pure product consisting only of the same enantiomer. 19−22 However, this method can only be used for chiral resolution when the compound crystallizes as a conglomerate.…”
Section: ■ Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…13−15 The importance of understanding the interaction between enantiomers of chiral compounds used as pharmaceuticals 16,17 has been highlighted through a recent report of a more stable racemic form of pioglitazone hydrochloride, which has been marketed as a conglomerate for many years. 18 One of the common, inexpensive methods to resolve the enantiomers of a compound on an industrial scale is the entrainment procedure, where the desired enantiomer is used as a seed in the crystallization step to obtain a pure product consisting only of the same enantiomer. 19−22 However, this method can only be used for chiral resolution when the compound crystallizes as a conglomerate.…”
Section: ■ Introductionmentioning
confidence: 99%
“…It often happens when the two enantiomers compete for the same position in its crystal lattice, and the term “pseudo racemates” has also been used to describe this phenomenon . Conglomerates are relatively rare, with this behavior observed for organic molecules about 5–10% cases in the Cambridge Structural Database, whereas racemates predominate and solid solutions occur rarely. The importance of understanding the interaction between enantiomers of chiral compounds used as pharmaceuticals , has been highlighted through a recent report of a more stable racemic form of pioglitazone hydrochloride, which has been marketed as a conglomerate for many years …”
Section: Introductionmentioning
confidence: 99%
“…Potentially, polymorphism can be realized for an enantiopure compound, and hence for the corresponding racemic conglomerates. The sustained interest in the peculiarities of “chiral” crystallization, observed recently, is largely due to the afore-mentioned legal aspects . Another reason is that the coexistence of different crystalline forms complicates the resolution of a chiral substance into enantiomers using preferential crystallization, the use of which opens up tempting industrial prospects. , It is believed that the probability of spontaneous resolution is low and amounts to ∼10%, although there are more optimistic estimates .…”
Section: Introductionmentioning
confidence: 99%
“…Polymorphism is an evergreen theme for researchers of molecular crystals. , Current interest in this problem is largely supported by the needs of pharmaceutical science and industry. , In recent years, chiral compounds are increasingly becoming objects of the research. An additional feature of chiral systems that is absent in the case of achiral substances is the possible interconversion of homochiral (scalemic, enantiopure) and heterochiral (mainly racemic) crystalline forms. In the strict sense of the word, conglomerate homochiral crystals are not polymorphic with respect to any racemic solid. However, like ordinary polymorphs, those and others can be formed from a common feed medium (solution or melt) and can transform into each other both as a result of solid-phase transitions and as a result of contact with the common liquid phase .…”
Section: Introductionmentioning
confidence: 99%
“…However, like ordinary polymorphs, those and others can be formed from a common feed medium (solution or melt) and can transform into each other both as a result of solid-phase transitions and as a result of contact with the common liquid phase . Lack of attention to this feature of a phase behavior of the chiral substance can lead to withdrawal of the dosage form from the market and/or the need for remarketing of the already registered drug …”
Section: Introductionmentioning
confidence: 99%